- DKK101.26bn
- DKK126.40bn
- $3.72bn
Europe Research Roundup: BASF SE, Beazley, Saint-Gobain
Brief: Genmab Says Johnson & Johnson Will Not Exercise Option For Hexabody-Cd38 License
Brief: Genmab Announces Johnson & Johnson Decision Regarding HEXABODY-CD38
Jyske Bank cheers Genmab shares despite worries over deal with J&J
Brief: Epkinly® (Epcoritamab) Approved By Japan Ministry Of Health, Labour And Welfare For Additional Indication As A Treatment For Relapsed Or Refractory Follicular Lymphoma
Brief: Epkinly Approved By Japan Ministry Of Health, Labour And Welfare
U.S. STOCKS ON THE MOVE-Genmab, Dutch Bros, Applovin
Genmab rises on better-than-expected Q4, guidance
Genmab rises on upbeat 2025 sales forecast
Genmab A/S reports results for the quarter ended December 31 - Earnings Summary
Brief: Genmab Sees 2025 Operating Profit At USD 0.9 - 1.4 Bln
Genmab A/S expected to post earnings of DKK25.52 a share - Earnings Preview
Brief: Genmab Darzalex 2024 Net Sales Totalled $11.67 Bln
Barclays cautious on European pharma in H1, sees re-rating chance in H2
RBC names specialty pharma and biotech launches to watch in 2025
Brief: Genmab Says Data Analyses Show Epcoritamab Induces Durable, Complete Responses in Patients With DLBCL
Brief: Genmab Says Investigational Epcoritamab Monotherapy Achieves High Overall And Complete Response Rates In Clinical Trial
Europe Research Roundup: Covivio, Mercedes-Benz Group, Persimmon
Jefferies cuts Genmab's PT by 23% on uncertain development pipeline